Epigenica closes successful investment round

Epigenica has completed a successful investment round in October, although the specific amount has not been disclosed. This development marks a critical step for the company as it prepares to launch its first product. The funding will provide the necessary resources to push forward with the product’s market debut and enhance its overall business operations.

Mohamad Takwa, the CEO of Epigenica, expressed his enthusiasm for the company's future, highlighting the excitement surrounding their product launch. "We are really looking forward to the coming period, bringing the launch of our first product to an exciting and important market," he said. This statement underscores the anticipation within the company as it prepares to introduce its innovative offering, which could represent a breakthrough in its field.

The closing of the investment round allows Epigenica to focus on refining its product and preparing for a smooth market entry. This additional capital likely strengthens the company’s operational capabilities, supporting critical areas such as research and development, marketing, and supply chain logistics. With these improvements in place, Epigenica is in a better position to ensure its product meets industry standards and customer expectations.